MARKET

ANCN

ANCN

ANCHIANO THERAPEUTICS LTD.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.020
-0.050
-4.67%
Opening 10:54 09/21 EDT
OPEN
1.030
PREV CLOSE
1.070
HIGH
1.060
LOW
1.020
VOLUME
18.41K
TURNOVER
--
52 WEEK HIGH
3.000
52 WEEK LOW
0.5136
MARKET CAP
37.84M
P/E (TTM)
0.1907
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aimmune Therapeutics rallies on Nestle acquiring, Akcea cheers Ionis acquiring 24% remaining stake, ADiTx Therapeutics and Lipocine among major losers
Gainers: Aimmune Therapeutics (AIMT) +172%, Akcea Therapeutics (AKCA) +60%, Pro-Dex (PDEX) +16%, Kindred Biosciences (KIN) +14%, Neuronetics (STIM) +11%.Losers: ADiTx Therapeutics (ADTX) -11%, Lipocine (LPCN) -11%, Orchard Therapeutics (ORTX) -11%, CNS Pharmaceuticals (CNSP) -9%, Anchiano Therapeutics (ANCN) -8%.
Seekingalpha · 08/31 14:58
VXRT, ONCS, CLSN and FUV among midday movers
Seeking Alpha - Article · 07/13 16:43
Anchiano Therapeutics 8-K Shows CEO Frank Haluska Sent Letter To Chair He Has Considered, Construes As Notice Of Constructive Resignation; Co. Received Notice From Danforth Advisors Of Intent To Terminate Consulting Deal
Benzinga · 07/09 20:20
EYES, SOLO, FOSL and VAL among midday movers
Seeking Alpha - Article · 06/09 16:45
Anchiano Appoints Stan Polovets as Chairman of the Board
Anchiano Therapeutics Ltd. (ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the board of Anchiano in April 2020. “We warmly welcome Stan as our new Chairman,” said Frank G.
GlobeNewswire · 05/26 12:00
ZYNE, CLSN, SNCA and SNDX among midday movers
Seeking Alpha - Article · 05/22 16:40
Anchiano Therapeutics EPS beats by $0.01
Anchiano Therapeutics (NASDAQ:ANCN): Q1 GAAP EPS of -$0.10 beats by $0.01. Cash and cash equivalents of ~$14M. Press Release
seekingalpha · 05/12 01:57
Anchiano Therapeutics Reports First Quarter 2020 Financial Results
GlobeNewswire · 05/11 21:01
More
No Data
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANCN stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 1.25M
% Owned: 3.37%
Shares Outstanding: 37.10M
TypeInstitutionsShares
Increased
0
0
New
3
387.46K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.15%
Pharmaceuticals & Medical Research
-2.84%
Key Executives
Chairman/Director
Stanislav Polovets
Chief Financial Officer
Steve DiPalma
Senior Vice President
Ronald Knickerbocker
Vice President
Sean Daly
Vice President - Research & Development
Michal Gilon Ohev-Zion
Other
Joseph Ginossar
Other
David Kerstein
Director
Isaac Kohlberg
Independent Director
Ruth Alon
Independent Director
Lawrence Howard
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ANCN stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ANCN
Anchiano Therapeutics Ltd, formerly known as ABioCancell Therapeutics Inc, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search and destroys paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Anchiano Therapeutics Ltd - ADR stock information, including NASDAQ:ANCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANCN stock methods without spending real money on the virtual paper trading platform.